The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center studyCitation formats

  • External authors:
  • Marianne Nordsmark
  • Julie Loncaster
  • Christina Aquino-Parsons
  • Shu Chuan Chou
  • Val Gebski
  • Jacob C. Lindegaard
  • Hanne Havsteen
  • Susan E. Davidson
  • Robin Hunter
  • James A. Raleigh
  • Jens Overgaard

Standard

The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. / Nordsmark, Marianne; Loncaster, Julie; Aquino-Parsons, Christina; Chou, Shu Chuan; Gebski, Val; West, Catharine; Lindegaard, Jacob C.; Havsteen, Hanne; Davidson, Susan E.; Hunter, Robin; Raleigh, James A.; Overgaard, Jens.

In: Radiotherapy and Oncology, Vol. 80, No. 2, 08.2006, p. 123-131.

Research output: Contribution to journalArticle

Harvard

Nordsmark, M, Loncaster, J, Aquino-Parsons, C, Chou, SC, Gebski, V, West, C, Lindegaard, JC, Havsteen, H, Davidson, SE, Hunter, R, Raleigh, JA & Overgaard, J 2006, 'The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study', Radiotherapy and Oncology, vol. 80, no. 2, pp. 123-131. https://doi.org/10.1016/j.radonc.2006.07.010

APA

Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S. C., Gebski, V., West, C., ... Overgaard, J. (2006). The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 80(2), 123-131. https://doi.org/10.1016/j.radonc.2006.07.010

Vancouver

Author

Nordsmark, Marianne ; Loncaster, Julie ; Aquino-Parsons, Christina ; Chou, Shu Chuan ; Gebski, Val ; West, Catharine ; Lindegaard, Jacob C. ; Havsteen, Hanne ; Davidson, Susan E. ; Hunter, Robin ; Raleigh, James A. ; Overgaard, Jens. / The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. In: Radiotherapy and Oncology. 2006 ; Vol. 80, No. 2. pp. 123-131.

Bibtex

@article{fc4defdd475341bc9a6cb382ca49bb0d,
title = "The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study",
abstract = "Background and purpose: Hypoxia adversely affects treatment outcome in human uterine cervical cancer. Here, we present the results of a prospective international multi-centre study evaluating the prognostic value of pre-treatment tumour oxygen partial pressure (pO 2) and the hypoxia marker pimonidazole (pimo). Materials and methods: One hundred and twenty-seven patients with primary cervix cancer were entered. Pre-treatment tumour pO 2 measurements were obtained, and reported by the median tumour pO 2, the fraction of pO 2 values ≤10 mmHg (HP 10), ≤5 mmHg (HP 5) and ≤2.5 mmHg (HP 2.5). Following intravenous pimonidazole administration, biopsies were taken, stained for pimonidazole adducts, and scored for the area of labelled tumour cells on a scale from 0 to 4. Treatment modalities were surgery (11{\%}), radiotherapy (98{\%}), chemotherapy (33{\%}) and carbogen (14{\%}). Results: None of the hypoxia descriptors were statistically significant prognostic factors for loco-regional tumour control or overall survival when analyzed as continuous variables or divided by the sample median. By univariate analysis only tumour size and nodal status were significant prognostic factors for local control. Tumour size and FIGO stage were significant for overall survival. In a multivariate analysis stratified by centre, only tumour size above 5 cm and lower pre-treatment haemoglobin predicted poorer overall survival among FIGO stage, nodal involvement, tumour size, pre-treatment haemoglobin dichotomized at 12 g/dl and pimo 1, pimo 4 and HP 5 as continuous variables. Conclusion: Neither Eppendorf nor pimonidazole should be dismissed based on the current results. However, further investigations are needed to readdress the hypotheses of the current study having optimized statistical designs, and a population of sufficient size treated more homogenously following rigorous protocols. {\circledC} 2006 Elsevier Ireland Ltd. All rights reserved.",
keywords = "Hypoxia marker, Pimonidazole, Tumour oxygenation, Uterine cervix carcinoma",
author = "Marianne Nordsmark and Julie Loncaster and Christina Aquino-Parsons and Chou, {Shu Chuan} and Val Gebski and Catharine West and Lindegaard, {Jacob C.} and Hanne Havsteen and Davidson, {Susan E.} and Robin Hunter and Raleigh, {James A.} and Jens Overgaard",
year = "2006",
month = "8",
doi = "10.1016/j.radonc.2006.07.010",
language = "English",
volume = "80",
pages = "123--131",
journal = "Radiotherapy & Oncology",
issn = "0167-8140",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - The prognostic value of pimonidazole and tumour pO 2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study

AU - Nordsmark, Marianne

AU - Loncaster, Julie

AU - Aquino-Parsons, Christina

AU - Chou, Shu Chuan

AU - Gebski, Val

AU - West, Catharine

AU - Lindegaard, Jacob C.

AU - Havsteen, Hanne

AU - Davidson, Susan E.

AU - Hunter, Robin

AU - Raleigh, James A.

AU - Overgaard, Jens

PY - 2006/8

Y1 - 2006/8

N2 - Background and purpose: Hypoxia adversely affects treatment outcome in human uterine cervical cancer. Here, we present the results of a prospective international multi-centre study evaluating the prognostic value of pre-treatment tumour oxygen partial pressure (pO 2) and the hypoxia marker pimonidazole (pimo). Materials and methods: One hundred and twenty-seven patients with primary cervix cancer were entered. Pre-treatment tumour pO 2 measurements were obtained, and reported by the median tumour pO 2, the fraction of pO 2 values ≤10 mmHg (HP 10), ≤5 mmHg (HP 5) and ≤2.5 mmHg (HP 2.5). Following intravenous pimonidazole administration, biopsies were taken, stained for pimonidazole adducts, and scored for the area of labelled tumour cells on a scale from 0 to 4. Treatment modalities were surgery (11%), radiotherapy (98%), chemotherapy (33%) and carbogen (14%). Results: None of the hypoxia descriptors were statistically significant prognostic factors for loco-regional tumour control or overall survival when analyzed as continuous variables or divided by the sample median. By univariate analysis only tumour size and nodal status were significant prognostic factors for local control. Tumour size and FIGO stage were significant for overall survival. In a multivariate analysis stratified by centre, only tumour size above 5 cm and lower pre-treatment haemoglobin predicted poorer overall survival among FIGO stage, nodal involvement, tumour size, pre-treatment haemoglobin dichotomized at 12 g/dl and pimo 1, pimo 4 and HP 5 as continuous variables. Conclusion: Neither Eppendorf nor pimonidazole should be dismissed based on the current results. However, further investigations are needed to readdress the hypotheses of the current study having optimized statistical designs, and a population of sufficient size treated more homogenously following rigorous protocols. © 2006 Elsevier Ireland Ltd. All rights reserved.

AB - Background and purpose: Hypoxia adversely affects treatment outcome in human uterine cervical cancer. Here, we present the results of a prospective international multi-centre study evaluating the prognostic value of pre-treatment tumour oxygen partial pressure (pO 2) and the hypoxia marker pimonidazole (pimo). Materials and methods: One hundred and twenty-seven patients with primary cervix cancer were entered. Pre-treatment tumour pO 2 measurements were obtained, and reported by the median tumour pO 2, the fraction of pO 2 values ≤10 mmHg (HP 10), ≤5 mmHg (HP 5) and ≤2.5 mmHg (HP 2.5). Following intravenous pimonidazole administration, biopsies were taken, stained for pimonidazole adducts, and scored for the area of labelled tumour cells on a scale from 0 to 4. Treatment modalities were surgery (11%), radiotherapy (98%), chemotherapy (33%) and carbogen (14%). Results: None of the hypoxia descriptors were statistically significant prognostic factors for loco-regional tumour control or overall survival when analyzed as continuous variables or divided by the sample median. By univariate analysis only tumour size and nodal status were significant prognostic factors for local control. Tumour size and FIGO stage were significant for overall survival. In a multivariate analysis stratified by centre, only tumour size above 5 cm and lower pre-treatment haemoglobin predicted poorer overall survival among FIGO stage, nodal involvement, tumour size, pre-treatment haemoglobin dichotomized at 12 g/dl and pimo 1, pimo 4 and HP 5 as continuous variables. Conclusion: Neither Eppendorf nor pimonidazole should be dismissed based on the current results. However, further investigations are needed to readdress the hypotheses of the current study having optimized statistical designs, and a population of sufficient size treated more homogenously following rigorous protocols. © 2006 Elsevier Ireland Ltd. All rights reserved.

KW - Hypoxia marker

KW - Pimonidazole

KW - Tumour oxygenation

KW - Uterine cervix carcinoma

U2 - 10.1016/j.radonc.2006.07.010

DO - 10.1016/j.radonc.2006.07.010

M3 - Article

VL - 80

SP - 123

EP - 131

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

SN - 0167-8140

IS - 2

ER -